48317770967_48ec28d656_b

Trump meets pharmaceutical executives to discuss COVID-19 vaccine

pharmafile | March 4, 2020 | News story | Research and Development COVID-19, Chinese Coronavirus, Trump, Wuhan Coronavirus, coronavirus 

President Trump has met with several representatives of the top pharmaceutical companies to discuss progress being made on a coronavirus vaccine.

Executives from Gilead Sciences, GlaxoSmithKline, Inovio pharmaceuticals, Moderna and Regeneron Pharmaceuticals were all in attendance.

Commenting on the gathering, Trump said: “They’re really working hard and they’re working smart. We had a great meeting with a lot of great companies. They’re going to have vaccines, I think, relatively soon, and they’re going to have something that makes you better, and that’s actually going to take place even sooner. I don’t know what the time will be. I’ve heard very quick numbers, that of months. And I’ve heard pretty much a year would be an outside number.”

However, Trump’s timeline does not seem realistic and Antony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said that a deployable vaccine is “going to be, at the earliest, a year to a year and a half.” This is backed up by the pharmaceutical companies with John Shiver, Senior Vice President of global vaccine R&D at Sanofi, who also attended the meeting, saying that a therapeutic for the virus could be developed “months or a very short amount of time, a year or so.”

Gilead’s drug remdesivir, originally developed for Ebola, has been tested since January on coronavirus patients and is currently in clinical trials.

Conor Kavanagh

 

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content